Skip Navigation

Cardiovascular Research 2000 45(1):65-67; doi:10.1016/S0008-6363(99)00297-7
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sen, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sen, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

The context: investigation into hypertension and cardiac hypertrophy

Subha Sen*

Department of Molecular Cardiology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA

* Tel.: +1-216-444-2056; fax: +1-216-444-2056 sens@ccf.org

KEYWORDS Blood pressure; Hypertension; Hypertrophy; Renal function

The first 150 words of the full text of this article appear below.


   1 Introduction
 
From the 1940s to the late 1960s, The Cleveland Clinic Foundation's Division of Research was a hub of advanced laboratory and clinical hypertension studies. Irvine H. Page, M.D., first chairman of Research, whose "mosaic theory of hypertension" outlined the multifactorial cardiovascular aspects of hypertension, was concentrating on the renin–angiotensin system in Clinic patients with both essential and renal hypertension. Page (and the City of Cleveland) became central to scientific interchange by founding the National Foundation for High Blood Pressure (precursor to the Council for High Blood Pressure Research of the American Heart Association).

Page had recruited F. Merlin Bumpus, Ph.D., in 1949 to investigate angiotensin and its antagonists; then, when high blood pressure was thought to be a ‘good’ response of the heart to stress, no one knew that the renin–angiotensin system was a control mechanism in hypertension. By 1969 Bumpus had synthesized angiotensin II, making that vasopressor peptide commercially . . . [Full Text of this Article]


   2 Scientific assumptions behind the research
 

   3 Why the reported findings have been cited
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?